Biotechnology
Biopharmaceutical
Pharmaceutical

Intercept Pharmaceuticals

$68.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.03 (-4.23%) Today
$0.00 (0.00%) As of 5:05 PM EDT after-hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!

About ICPT

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Employees
483
Headquarters
New York, New York
Founded
2002
Market Cap
2.04B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
846.49K
High Today
$72.21
Low Today
$68.41
Open Price
$72.21
Volume
964.08K
52 Week High
$133.74
52 Week Low
$68.20

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Research And Development
Technology

ICPT News

Yahoo FinanceJun 21

An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. Suggests It's 43% Undervalued

640

ICPT Earnings

-$4.43
-$3.68
-$2.93
-$2.18
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market

Popular Stocks

More ICPT News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.